Please assess the completion status of the following clinical trial:

Trial Title: Comparative Study to Evaluate the Efficacy and Safety of MYL-1701P and Eylea® in Subjects With Diabetic Macular Edema (DME)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Male or female subjects age ≥ 18 years.~2. Subjects have type 1 or type 2 diabetes mellitus who present with central DME involvement in the study eye.~3. The cause of decreased vision in the study eye has been attributed primarily to DME by the Investigator.~4. Subject is able to understand and voluntarily provide written informed consent to participate in the study.~5. If female of child bearing potential, the subject must have a negative serum pregnancy test at the Screening visit and a negative urine pregnancy test at baseline visit, and should not be nursing or planning a pregnancy.~6. If female, subject must be:~   1. Surgically sterilized via hysterectomy, bilateral oophorectomy, or bilateral tubal ligation; or~  2. Of childbearing potential and practicing an acceptable form of birth control (defined as the use of an intrauterine device; a barrier method, like condom, with spermicide; any form of hormonal contraceptives; or abstinence from sexual intercourse) starting 60 days prior to dosing and continuing at least 90 days following the last treatment.~  3. Of non-childbearing potential (i.e., postmenopausal for at least 1 year).~7. If male, subject must be surgically or biologically sterile. If not sterile, the subject must agree to use an acceptable form of birth control with sexual partner (as described in inclusion criteria #6b of protocol) or abstain from sexual relations during the study period and up to 90 days following the last treatment dose.~8. Subject is willing to comply with the study duration, study visits and study related procedures.~Exclusion Criteria:~1. Subjects with known hypersensitivity to aflibercept or any of the excipients~2. Subjects with current or planned use of systemic medications known to be toxic to the lens, retina or optic nerve, including deferoxamine, chloroquine/hydroxychloroquine, tamoxifen, phenothiazines and ethambutol~3. Subjects with uncontrolled hypertension defined as systolic blood pressure \>160mm Hg or diastolic blood pressure \> 95 mm of Hg.~4. Subjects with a history of cerebrovascular accident or myocardial infarction within 6 months of randomization.~5. Subjects with history of use of intraocular corticosteroids anytime in the past or periocular (subconjunctival, intra-scleral, sub-tenon or retrobulbar) corticosteroids within 4 months of randomization~6. Subjects who have only one functional eye, even if the eye met all other study requirements, or who have an ocular condition on the fellow eye with a poorer prognosis than the study eye.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- MYL-1701P (Type: EXPERIMENTAL): MYL-1701P
- Eylea (Type: ACTIVE_COMPARATOR): Eylea

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete